BC
MLYS icon

Bridgefront Capital’s Mineralys Therapeutics MLYS Stock Holding History

Bridgefront Capital’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,338
Closed -$240K – 685
2025
Q3 		$240K Buy
+6,338
New +$137K 0.07% 465

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Bridgefront Capital's MLYS Position: Q4 2025 in Review

Bridgefront Capital sold out of Mineralys Therapeutics (MLYS) in Q4 2025, closing a stake of 6,338 shares — an estimated $240K sold.

Bridgefront Capital first reported a position in MLYS in Q3 2025 and held it in 1 quarter. The position peaked at $240K in Q3 2025. 223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

  • Bridgefront Capital reported no remaining Mineralys Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bridgefront Capital sold 6,338 Mineralys Therapeutics shares in Q4 2025, an estimated $240K.
  • Bridgefront Capital first reported a position in Mineralys Therapeutics in Q3 2025 and held it in 1 quarter.
  • Bridgefront Capital's Mineralys Therapeutics position peaked at $240K in Q3 2025.
  • 223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.